Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (1366)	5/14/1998 9:56:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 2173

D.Right, Actually, the number of Biotechs that I have made negative post about is quite limited. In general, I like Biotechs. I think that they will richly reward astute investors as well as mankind in general. Readers of this board may have a somewhat distorted view of my posts. The two "Biotechs" that I disliked the most really had little to do with LGND (and many, including myself, would not even call them Biotechs). Those posts began in my old Prodigy days. One of the companies was CHTL. It was trading in the mid 20's with a market cap of about $1 Billion. Although it's product could be considered a competitor for LGND, I really didn't put the product in the same category. In fact I didn't even consider CHTL a Biotech. It seemed more like an infomercial than anything else. I was asked about their ability to take a drug to market. When I saw that they only had 43 employees and the company, CEO, President, COO, and media contact all had the same first name, I thought that there might be a problem. I issued some warnings and was threatened with lawsuits by over zealous investors (or hypsters). When I summarized an upcoming Barron's article, I was accused of leading a bear raid. I really haven't followed CHTL that closely lately, but did notice that today it closed at $0.061, a far cry from the mid 20's. Another company that I loved to hate was BICO. They were more modestly priced (around $6) but put out some of the worst written press releases that I had ever seen. There were hundreds of millions of shares outstanding and their lead product seemed antiquated long before it had a chance of approval and the FDA submission also seemed to be among the worst that I had seen. BICO closed today at 1/16. However, among true Biotechs, I have really not been very negative. In the past I had recommended AMLN and was consequently somewhat disappointed by their Phase III data. I had been asked to comment here, by a regular AMLN poster (who has since taken up residence on the LGNDboard). I did give my take on the data which was shared by the street and then by JNJ. The only other negative comments that I have made on a product was Ergoset. Again I was asked to evaluate the data and again was not impressed. I have upset a few on the AGPH board when I indicated that resistance to PIs would develop. I really wasn't knocking the company or product, just giving my scientific opinion of what would happen in the future. In summary, my negative posts have been rather limited although some readers of this board would be somewhat surprised.